{
  "docId": "019de073-a38b-741c-ac33-1ee77869cf6c",
  "docSlug": "1556a4546991601fbfe098864d52433b",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 36,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a38b-741c-ac33-1ee77869cf6c/22",
  "deckHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c",
  "deckJsonHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c.json",
  "deckAnchorHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.371,
        "y": 0.27
      },
      "kind": "chart",
      "text": "T-Scores for HVLT, Symbol Coding, and Category Fluency across 10mg, 20mg, 40mg, 80mg doses",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22b3638b-1b0e-4b9a-af57-75e5401c9239",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.371,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Completed Phase 2 PoM Trial timeline showing cohorts, dosing, and endpoints",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af86372d-2edb-4a9e-b724-0b6de8c36a2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.371,
        "y": 0.11
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b71639ff-5265-4254-9cf5-bde2fa1b6819",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.371,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; RL-007 is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt; TID denotes 3x/day dosing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3cd8fb2-06d5-4b3b-89e4-3d576c012a9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.34,
        "x": 0.015,
        "y": 0.16
      },
      "kind": "table",
      "text": "Ownership: 51.9%, Product: RL-007, Pharmacology: Cholinergic/Glutamatergic/GABA-B, Features: No SAEs, Indications: CIAS/Autism/Alzheimer's, Status: Phase 2a complete, IP: Issued patents, Highlight: Phase 2 in 180 patients",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bdf652b-83a8-4e72-b99b-507ae1dc5d23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.371,
        "y": 0.035
      },
      "kind": "title",
      "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10436b69-c05c-4920-84d6-288bd25d5a1b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "f73f91ff-f1a8-47f4-9fae-b8114ed177e3",
      "evidence": "The slide is titled 'RL-007 has previously shown pro-cognitive effects in human clinical studies' and has a type labeled as 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "27daf5ee-fa83-49bf-9f5e-3b09b41973d9",
      "evidence": "Structured summary of product, pharmacology, status, and clinical data.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}